Papillary Thyroid Carcinoma

9 · 20 / page

Ask MedXY AI

Latest news

Tag

Diabetes & Endocrinologyantithyroglobulin antibodiesPapillary Thyroid Carcinoma

Detectable Antithyroglobulin Antibodies Above the Assay LOQ Signal Higher Recurrence Risk in Papillary Thyroid Carcinoma Despite Undetectable Thyroglobulin

By MedXY|Jun 3, 2026

In papillary thyroid carcinoma treated with thyroidectomy and RAI, TgAb levels above the assay’s limit of quantification identified patients with higher long-term recurrence risk despite undetectable serum thyroglobulin.

ATA Guideline Updates Reduced Thyroid Cancer Overtreatment in a 31,861-Patient South Korean Cohort

General Surgery

Papillary Thyroid Carcinoma

Latest news

Detectable Antithyroglobulin Antibodies Above the Assay LOQ Signal Higher Recurrence Risk in Papillary Thyroid Carcinoma Despite Undetectable Thyroglobulin

ATA Guideline Updates Reduced Thyroid Cancer Overtreatment in a 31,861-Patient South Korean Cohort

Validation of the 2025 ATA Risk Stratification System in a Cohort of Patients with Papillary Thyroid Carcinoma

2025 ATA Risk Stratification for Papillary Thyroid Cancer: Validation Study Reveals Significant Reclassification Shifts

Rethinking Radical Surgery: Lobectomy Matches Total Thyroidectomy Outcomes in Intermediate-Risk PTC with Unilateral N1b Disease

Rethinking Radioactive Iodine Therapy for T1-T2 Papillary Thyroid Carcinoma with Lymph Node Metastasis: A Multicenter Analysis

Total Thyroidectomy Superior to Lobectomy for N1b Papillary Thyroid Carcinoma: Longitudinal Data Suggests Age-Dependent Survival Benefits

De-escalating Management of N1b Papillary Thyroid Carcinoma: Are Total Thyroidectomy and RAI Mandatory for All?

Thyroid Lobectomy and Neck Dissection Offer Comparable Survival to Total Thyroidectomy in Selected N1b Papillary Thyroid Carcinoma